On September 7, 2021 Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, reported that it will webcast its presentation at the Morgan Stanley 19th Annual Global Healthcare Conference at 2:00 p.m. PT on Monday, September 13, 2021 (Press release, Sana Biotechnology, SEP 7, 2021, View Source [SID1234587297]). The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast will be accessible on the Investor Relations page of Sana’s website at View Source A replay of the presentation will be available at the same location for 30 days following the conference.

On September 7, 2021 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, reported that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the H.C. Wainwright 23rd Annual Global Investment Conference (Press release, Revolution Medicines, SEP 7, 2021, View Source [SID1234587296]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the company’s participation are as follows:

H.C. Wainwright 23rd Annual Global Investment Conference
Conference Dates: September 13-15, 2021
Presentation Timing: 7:00 a.m. Eastern on Monday, September 13, 2021
Format: Virtual conference; webcast available
To access the live webcast of the presentation, please visit the "Events & Presentations" page of Revolution Medicines’ website at View Source Additionally, a replay of the webcast will be available on the "Events & Presentations" page of the Revolution Medicines website for at least 14 days following the conference.

On September 7, 2021 Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, reported that the Company’s management will participate in two upcoming investor conferences in September (Press release, Corvus Pharmaceuticals, SEP 7, 2021, View Source [SID1234587295]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first conference is the H.C. Wainwright Annual Global Investment Conference, which is taking place September 13-15, 2021. The Company will conduct one-on-one meetings with investors at this conference and a pre-recorded corporate overview presentation by Richard A. Miller, M.D., president and chief executive officer of Corvus, will be available to play on-demand starting at 7:00 am ET on September 13. Attendees can register to view the webcast here.

The second conference is the Cantor Virtual Global Healthcare Conference, which is taking place September 27-30, 2021. The Company will conduct one-on-one meetings with investors at this conference and a virtual corporate overview presentation will be conducted by Dr. Miller at 3:20-3:50 pm ET on September 29. Attendees can register for the virtual presentation here.
Attendees can also access the webcast of the presentations noted above via the investor relations section of the Corvus website and replays will be available for 90 days following the events.

On September 7, 2021 Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, reported that members of its management team will present at the following investor conferences in September 2021 (Press release, Alpine Immune Sciences, SEP 7, 2021, View Source [SID1234587294]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 23rd Annual Global Investment Conference
Date: Monday, September 13, 2021
Time: Available on demand beginning 7:00 a.m. ET/4:00 a.m. PT
Event: Company Presentation

Oppenheimer Fall Healthcare Summit
Date: Monday, September 20, 2021
Time: 2:55 p.m. ET/11:55 a.m. PT
Event: Fireside Chat

Cantor Global Healthcare Conference
Date: Wednesday, September 29, 2021
Time: 2:00 p.m. ET/11:00 a.m. PT
Event: Company Presentation

Webcasts of the H.C. Wainwright, Oppenheimer, and Cantor presentations will be available online in the investor relations section of the company’s website at View Source A replay of the presentations will be available on the company website for 90 days following the webcast.

On September 7, 2021 Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, reported that the first patient has been treated in a Phase 2 clinical trial evaluating BDB001 in advanced solid tumors at The University of Texas MD Anderson Cancer Center in Houston, TX (Press release, Seven and Eight Biopharmaceuticals, SEP 7, 2021, View Source [SID1234587293]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BDB001 is an intravenously administered Toll-Like Receptor 7 and 8 (TLR 7/8) dual agonist specifically designed to enhance immune activation against cancer. BDB001 has shown to be well tolerated as monotherapy and in combination with an anti-PD-1 mAb, with responses seen in multiple advanced solid tumor types (SITC, 20201; ASCO (Free ASCO Whitepaper), 20212).

BDB001-201 (NCT04819373) is an open-label, multi-arm Phase 2 clinical trial evaluating the efficacy, safety and tolerability of BDB001 in patients with advanced solid tumors that have progressed on anti-PD-1 or anti-PD-L1 mAb treatment.

"There is significant unmet need for effective treatment options for patients with anti-PD-1 / anti-PD-L1 refractory tumors," said Dr. Robert H.I. Andtbacka, Chief Medical Officer, Seven and Eight Biopharma. "In our BDB001 Phase 1 clinical trial there was evidence of response in these tumors. We are excited to further explore the role of BDB001 in anti-PD-1 / anti-PD-L1 refractory tumors in a Phase 2 setting."

"As an intravenously administered TLR 7/8 agonist, BDB001 has the potential to become a cornerstone of cancer immunotherapy. This Phase 2 program is an important milestone in our mission at Seven and Eight Biopharma, to develop novel treatments for cancer that expand immuno-oncology beyond PD-1, PD-L1, and CTLA-4." said Dr. Walter Lau, Chief Executive Officer, Seven and Eight Biopharma.